Validation of the freezing of gait questionnaire in patients with Parkinson's disease |
| |
| Authors: | Nir Giladi MD Joseph Tal PhD Tali Azulay MSc Oliver Rascol MD PhD David J. Brooks MD DSc Eldad Melamed MD Wolfgang Oertel MD Werner H. Poewe MD Fabrizio Stocchi MD Eduardo Tolosa MD |
| |
| Affiliation: | 1. Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel;2. TechnoStat Ltd, Hod Hasharon, Israel;3. Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex, France;4. Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom;5. Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel;6. Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg, Germany;7. Department of Neurology, University of Innsbruck, Innsbruck, Austria;8. Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy;9. Neurology Department, Hospital Clinic, Barcelona, Spain |
| |
| Abstract: | To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society |
| |
| Keywords: | freezing of gait validation Parkinson's disease rasagiline |
|
|
